Literature DB >> 32323264

Association of the polymorphisms of the genes APOC3 (rs2854116), ESR2 (rs3020450), HFE (rs1799945), MMP1 (rs1799750) and PPARG (rs1801282) with lipodystrophy in people living with HIV on antiretroviral therapy: a systematic review.

Andreia Soares da Silva1, Tatiana Lins Carvalho2, Kleyton Palmeira do Ó3, Débora Nascimento da Nóbrega4, Roberta Dos Santos Souza4, Victor Fernando da Silva Lima5, Isabela Cristina Cordeiro Farias5, Taciana Furtado de Mendonça Belmont5, Maria do Socorro de Mendonça Cavalcanti5, Demócrito de Barros Miranda-Filho5.   

Abstract

The aim of this study was to perform a systematic review to identify data reported in the literature concerning the association of APOC3 (rs2854116), ESR2 (rs3020450), HFE (rs1799945), MMP1 (rs1799750) and PPARG (rs1801282) polymorphisms with lipodystrophy in people living with HIV (PLWHIV) on antirretroviral therapy. The research was conducted in six databases and the studies were selected in two steps. First, a search was undertaken in the following electronic databases: PubMed, Science Direct, Medline, World Wide Science, Directory of Open Access Journals, Scielo, Lilacs and Medcarib. The titles and abstracts of 24,859 articles were read to select those that match the elegibilty criteria. Five papers that addressed the association of HAART, lipodystrophy and polymorphisms were selected for the review. There was no association between the polymorphisms of the genes APOC3 and PPARG and lipodystrophy. Another study described an association between the variant allele (G) of HFE and protection concerning the development of lipoatrophy (0.02) when compared with the reference allele (C). On the other hand, the variant allele (T) of the ESR2 gene was associated with the development of lipoatrophy (p = 0.007) when compared with the reference allele (C). In addition, the genotype and the variant allele of the gene MMP1 (2G) were associated with lipodystrophy in PLWHIV on HAART (p = 0.0002 and p = 0.0008, respectively). Therefore, further studies with other populations, involving PLWHIV on HAART are necessary to better understand the role of genetic markers, which may be involved in a predisposition to lipodystrophy.

Entities:  

Keywords:  APOC3; Antiretroviral therapy; ESR2; HFE; HIV; MMP1; PPARG; Polymorphisms

Mesh:

Substances:

Year:  2020        PMID: 32323264     DOI: 10.1007/s11033-020-05441-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  57 in total

Review 1.  Nutrition and the HIV-associated lipodystrophy syndrome.

Authors:  Cathríona Rosemary Loonam; Anne Mullen
Journal:  Nutr Res Rev       Date:  2012-12       Impact factor: 7.800

Review 2.  HIV cure research: advances and prospects.

Authors:  Caroline P Passaes; Asier Sáez-Cirión
Journal:  Virology       Date:  2014-03-11       Impact factor: 3.616

Review 3.  The HIV-1/HAART associated metabolic syndrome - novel adipokines, molecular associations and therapeutic implications.

Authors:  S Tsiodras; A Perelas; C Wanke; C S Mantzoros
Journal:  J Infect       Date:  2010-06-12       Impact factor: 6.072

4.  Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.

Authors:  Catherine L Cherry; Luxshimi Lal; Katherine A Thompson; Catriona A McLean; Lisa L Ross; Jaime Hernandez; Steven L Wesselingh; Grace McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2005-03-01       Impact factor: 3.731

Review 5.  Lipid Management in Human Immunodeficiency Virus.

Authors:  Merle Myerson
Journal:  Endocrinol Metab Clin North Am       Date:  2016-03       Impact factor: 4.741

Review 6.  Human immunodeficiency virus & cardiovascular risk.

Authors:  Giuseppe Barbaro; Giorgio Barbarini
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

Review 7.  The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.

Authors:  John Palios; Nikolaos P E Kadoglou; Stylianos Lampropoulos
Journal:  Exp Diabetes Res       Date:  2011-12-08

8.  Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia.

Authors:  Gizachew Ayele; Belay Tessema; Anteneh Amsalu; Getachew Ferede; Gizachew Yismaw
Journal:  BMC Immunol       Date:  2018-12-17       Impact factor: 3.615

9.  Genetic markers associated to dyslipidemia in HIV-infected individuals on HAART.

Authors:  Rosmeri K Lazzaretti; Aline S Gasparotto; Marina G de M Sassi; Carísi A Polanczyk; Regina Kuhmmer; Jussara M Silveira; Rossana P Basso; Cezar A T Pinheiro; Mariângela F Silveira; Eduardo Sprinz; Vanessa S Mattevi
Journal:  ScientificWorldJournal       Date:  2013-09-26

10.  Sexual behaviours of HIV positive adults receiving HAART in Botswana: a cross sectional study.

Authors:  Mpho Keetile; Gofaone Kgosidintsi
Journal:  Afr Health Sci       Date:  2018-09       Impact factor: 0.927

View more
  1 in total

Review 1.  Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals.

Authors:  Angélica Saraí Jiménez-Osorio; Sinaí Jaen-Vega; Eduardo Fernández-Martínez; María Araceli Ortíz-Rodríguez; María Fernanda Martínez-Salazar; Reyna Cristina Jiménez-Sánchez; Olga Rocío Flores-Chávez; Esther Ramírez-Moreno; José Arias-Rico; Felipe Arteaga-García; Diego Estrada-Luna
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.